Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers

被引：4

作者：

Proulx, L. ^{[1
]}

Bourgault, B. ^{[1
]}

Chauret, N. ^{[1
]}

Larouche, R. ^{[2
]}

Tanguay, M. ^{[2
]}

Thibert, R. ^{[1
]}

机构：

[1] ViroChem Pharma Inc, Laval, PQ, Canada

[2] Anapharm A PharmaNet Co, Montreal, PQ, Canada

来源：

JOURNAL OF HEPATOLOGY | 2008年 / 48卷

关键词：

D O I：

10.1016/S0168-8278(08)60856-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

854

引用

页码：S320 / S321

页数：2

共 50 条

[1] SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION
Lawitz, E.
Cooper, C.
Rodriguez-Torres, M.
Ghalib, K.
Lalonde, R.
Sheikh, A.
Bourgault, B.
Chauret, N.
Proulx, L.
McHutchison, J.
JOURNAL OF HEPATOLOGY, 2009, 50 : S37 - S37
[2] SAFETY, AND TOLERABILITY OF NIM811, A NOVEL CYCLOPHILIN INHIBITOR FOR HCV, FOLLOWING SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND HCV-INFECTED PATIENTS
Ke, J.
Lawitz, E.
Rozier, R.
Marbury, T.
Nguyen, N.
Serra, D.
Dole, K.
Praestgaard, J.
Huang, M.
Evans, T.
JOURNAL OF HEPATOLOGY, 2009, 50 : S229 - S229
[3] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PSI-352938, A NOVEL NUCLEOTIDE POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY SUBJECTS
Symonds, William
Denning, Jill M.
Albanis, Efsevia
Wright, Robert
Lai, Alexander
Berrey, Michelle
HEPATOLOGY, 2010, 52 (04) : 1219A - 1219A
[4] PHARMACOKINETICS, TOLERABILITY AND EFFECT OF FOOD ON HCV POLYMERASE INHIBITOR ABT-333 FOLLOWING SINGLE ASCENDING DOSES IN HEALTHY ADULT VOLUNTEERS
Menon, R.
Cohen, D.
Nada, A.
Dumas, E. Olson
Chiu, Y. -L.
Podsadecki, T.
Awni, W.
Bernstein, B.
Klein, C.
JOURNAL OF HEPATOLOGY, 2009, 50 : S347 - S348
[5] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS
Cooper, C.
Larouche, R.
Bourgault, B.
Chauret, N.
Proulx, L.
JOURNAL OF HEPATOLOGY, 2009, 50 : S342 - S342
[6] Single ascending dose safety, tolerability, and pharmacokinetic study of econazole in healthy volunteers
Khera, Himanshi
Pandey, Avaneesh Kumar
Shafiq, Nusrat
Khuller, G. K.
Bhandari, Ritika Kondel
Panditrao, Aditi
Gamad, Nanda
Rohilla, Rachna
Bhattacharjee, Samiksha
Murali, Naveen
Cvn, Harish
Belavagi, Devraj
Mothsara, Chakrant
Singh, Manjula
Sharma, Navneet
Behera, Digamber
Malhotra, Samir
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (06) : 955 - 961
[7] ANTIVIRAL ACTIVITY, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PSI-7851, A NOVEL NUCLEOTIDE POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE AND 3 DAY MULTIPLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC HCV INFECTION
Rodriguez-Torres, Maribel
Lawitz, Eric
Flach, Stephen
Denning, Jill M.
Albanis, Efsevia
Symonds, William
Berrey, M. M.
HEPATOLOGY, 2009, 50 (06) : 11A - 11A
[8] RESULTS OF A PHASE I SAFETY TOLERABILITY AND PHARMACOKINETIC STUDY OF ANA598, A NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR, IN HEALTHY VOLUNTEERS
Rahimy, Mohamad H.
Crowley, Constance A.
Freddo, James L.
Sergeeva, Maria V.
Golec, Brent
HEPATOLOGY, 2008, 48 (04) : 1026A - 1026A
[9] A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.
Sayegh, L.
Rufiange, M.
Sadoune, A. Ait
Sicard, E.
Massicotte, J.
Lefebvre, M.
Colin, P.
Ranger, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S63 - S64
[10] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR PF-00868554 FOLLOWING MULTIPLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS
Hammond, Jennifer L.
Purohit, Vivek S.
Fang, Juanzhi
DeBruin, Michael F.
HEPATOLOGY, 2008, 48 (04) : 1159A - 1160A

← 1 2 3 4 5 →